Aethlon Medical study links Long COVID biomarker to Hemopurifier
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St futures ease as Big Tech results revive AI spending worries; oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Dollar hits fresh 40-year high versus yen, edges down against euro
- Oil prices rise for a fifth day as US-Iran hostilities threaten supply routes
Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®
June 26, 2026 8:01 AM EDTPeer-reviewed study identifies altered extracellular vesicles in Long COVID and provides additional scientific rationale for evaluating the Hemopurifier® as a potential treatment
SAN DIEGO, June 26, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced publication of new peer-reviewed research in the International Journal of Molecular Sciences... More
